eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT02767804)

🧪 Interventions in This Study

• X-396 (ensartinib) (DRUG)
• crizotinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (72 Sites)

Showing the first 25 of 72 sites.

• Moffitt Cancer Center — Tampa, Florida
• University Cancer & Blood Center — Athens, Georgia
• Washington University School of Medicine — St Louis, Missouri
• Providence Portland Medical Center — Portland, Oregon
• Sanatorio Parque S.A. — Rosario,
• Border Medical Oncology Research Unit — Albury, New South Wales
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Chris O Brien Lifehouse — Camperdown,
• Catholic University of Louvain (UCL) - Site Mont Godinne — Yvoir,
• Instituto do Câncer do Estado de São Paulo — São Paulo, São Paulo
• Hospital de Câncer de Barretos - Fundação Pio XII — São Paulo, São Paulo
• Hospital Haroldo Juaçaba - Instituto do Cancêr do Ceará — Fortaleza,
• Fundacao do ABC Faculdade de Medicina do ABC — São Paulo,
• Infirmière recherche Clinique, IUCPQ — Québec, Quebec
• Anhui Provincial Hospital — Hefei, Anhui
• Beijing Chao Yang Hospital — Beijing, Beijing Municipality
• Peking Union Medical College Hospital — Beijing, Beijing Municipality
• Peking University Cancer Hospital — Beijing, Beijing Municipality
• Beijing Chest Hospital,Capital Medical University — Beijing, Beijing Municipality
• Fujian Provincial Cancer Hospital — Fuzhou, Fujian
• Guangdong General Hospital — Guangzhou, Guangdong
• Fourth Hospital of Hebei Medical University — Shijiazhuang, Hebei
• Hunan Cancer Hospital — Changsha, Hu'nan
• Union Hospital of Tongji Medical College of Huazhong Science and Techology University — Wuhan, Hubei
• Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology — Wuhan, Hubei

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-small Cell Lung Cancer

• Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona

Explore by condition: All Non-small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.